Early Clopidogrel Versus Prasugrel Use Among Contemporary STEMI and NSTEMI Patients in the US: Insights From the National Cardiovascular Data Registry
Open Access
- 24 March 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 3 (2) , e000849
Abstract
Background: P2Y12 antagonist therapy improves outcomes in acute myocardial infarction ( MI ) patients. Novel agents in this class are now available in the US . We studied the introduction of prasugrel into contemporary MI practice to understand the appropriateness of its use and assess for changes in antiplatelet management practices. Methods and Results: Using ACTION Registry‐ GWTG (Get‐with‐the‐Guidelines), we evaluated patterns of P2Y12 antagonist use within 24 hours of admission in 100 228 ST elevation myocardial infarction (STEMI) and 158 492 Non‐ST elevation myocardial infarction (NSTEMI) patients at 548 hospitals between October 2009 and September 2012. Rates of early P2Y12 antagonist use were approximately 90% among STEMI and 57% among NSTEMI patients. From 2009 to 2012, prasugrel use increased significantly from 3% to 18% (5% to 30% in STEMI ; 2% to 10% in NSTEMI ; P for trend <0.001 for all). During the same period, we observed a decrease in use of early but not discharge P2Y12 antagonist among NSTEMI patients. Although contraindicated, 3.0% of patients with prior stroke received prasugrel. Prasugrel was used in 1.9% of patients ≥75 years and 4.5% of patients with weight <60 kg. In both STEMI and NSTEMI , prasugrel was most frequently used in patients at the lowest predicted risk for bleeding and mortality. Despite lack of supporting evidence, prasugrel was initiated before cardiac catheterization in 18% of NSTEMI patients. Conclusions: With prasugrel as an antiplatelet treatment option, contemporary practice shows low uptake of prasugrel and delays in P2Y12 antagonist initiation among NSTEMI patients. We also note concerning evidence of inappropriate use of prasugrel, and inadequate targeting of this more potent therapy to maximize the benefit/risk ratio.Keywords
This publication has 35 references indexed in Scilit:
- Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary SyndromesNew England Journal of Medicine, 2013
- On- Versus Off-Label Use of Drug-Eluting Coronary Stents in Clinical Practice (Report from the American College of Cardiology National Cardiovascular Data Registry [NCDR])The American Journal of Cardiology, 2006
- Clopidogrel to Treat Patients With Non–ST-Segment Elevation Acute Coronary Syndromes After Hospital DischargeArchives of internal medicine (1960), 2006
- Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trialThe Lancet, 2005
- Effect of Clopidogrel Pretreatment Before Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction Treated With FibrinolyticsThe PCI-CLARITY StudyJAMA, 2005
- Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment ElevationNew England Journal of Medicine, 2005
- A Validated Prediction Model for All Forms of Acute Coronary SyndromeJAMA, 2004
- Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment ElevationNew England Journal of Medicine, 2001
- Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE studyThe Lancet, 2001
- Using information technology to reduce rates of medication errors in hospitalsBMJ, 2000